AFMDQ OTC

Affimed N.V. operates as a clinical-stage biopharmaceutical firm, dedicated to the discovery and advancement of immunotherapies targeting cancer across both the United States and Germany. Its primary therapeutic candidates include AFM13, which has successfully concluded Phase 2 trials for CD30-positive lymphoma, Phase 1b for Hodgkin lymphoma, and Phase 2b clinical evaluation for peripheral T-cell lymphoma. Another key candidate, AFM24, a tetravalent, bispecific innate cell engager designed to bind epidermal growth factor receptor and CD16A, is currently undergoing a Phase 2a clinical trial for patients with advanced malignancies. Additionally, AFM28, another innate cell engager (ICE), is in preclinical stages for addressing acute myeloid leukemia. Similarly, AFM32, an ICE candidate, is progressing through preclinical development for solid tumor indications. The company also maintains a collaborative partnership with Artiva Biotherapeutics, aiming to develop the combined therapy of acimtamig and AlloNK. Furthermore, a licensing and strategic alliance with Roivant Sciences Ltd. focuses on the development and commercialization of new ICE molecules, notably AFM32, within the field of oncology. A strategic collaboration with Genentech is also in place for advancing specific product candidates, encompassing novel NK cell engager-based immunotherapeutic agents designed to combat a range of cancers. Formerly named Affimed Therapeutics B.V., the entity adopted its current moniker, Affimed N.V., in October 2014. Established in 2000, its corporate headquarters are situated in Mannheim, Germany.